Datametrex AI (TSXV: DM) is one step closer to offering a full service telemedicine app. The company this morning indicated that its Medi-Call MD subsidiary has entered the beta test stage of its phone app, with a closed beta now being launched for patients.
Select patients are to be enrolled within the beta program, with the first webinar on the application to take place at the end of the month. The firm did not indicate which mobile platform has been selected for beta testing, however both Android and Apple apps are anticipated to be released once testing is complete.
The Medi-Call platform has been designed as a subscription service, enabling patients to reach a doctor through the use of their phone to obtain health services, which is said to include prescriptions. Upon download, users are to enter their medical information as well as their preferred pharmacy location prior to being connected with a doctor. After the visit, any required prescription will be automatically forwarded to their pharmacy of choice.
Sponsored · PTX Metals Inc.
Commenting on the development, Datametrex CEO Marshall Gunter stated, “Medi-Call app is leveraging advanced technology to help bring accessible, affordable healthcare services to patients with doctors supporting Canadians to take greater ownership of their health and wellness outcomes outside of doctor offices and emergency rooms leading to improved health.”
The Medi-Call app is intended to increase the accessibility of quality healthcare to patients, with the company placing an emphasis on those of whom live in rural or isolation communities, as well as those with limited time, transportation, or mobility.
Datametrex AI last traded at $0.17 on the CSE.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
